Jci_page_head_homepage_01 Jci_page_head_homepage_02
Gilles Faury, Mylène Pezet, Russell H. Knutsen, Walter A. Boyle, Scott P. Heximer, Sean E. McLean, Robert K. Minkes, Kendall J. Blumer, Attila Kovacs, Daniel P. Kelly, Dean Y. Li, Barry Starcher, Robert P. Mecham
Published in Volume 112, Issue 9
J Clin Invest. 2003; 112(9):1419–1428 doi:10.1172/JCI19028
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 4

Alteration in MAP after intravenous injection of Ang II or Ang I receptor antagonists. (a) Maximal change in MAP in response to a bolus dose (1 μg/kg i.v.; n = 8 for Eln+/+, n = 3 for Eln+/–) of Ang II. (b) Blood pressure change in response to infusion of saralasin (10 μg/kg; n = 2 for each phenotype) and candesartan (100 μg/kg; n = 3 for Eln+/+, n = 5 for Eln+/–). Error bars show SEM. *Significant difference (P ≤ 0.05, t test) between treated and control vessels within each genotype.